Refractory Angina Treatment Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Refractory Angina Treatment Market is segmented By Drug Development (Clinical, Preclinical, Discovery), By Route of Administration (Oral, Intravenous, Subcutaneous, Parenteral), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD million) for the above-mentioned segments.
Refractory Angina Treatment Market Size
Market Size in USD
CAGR5.4%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 5.4% |
| Market Concentration | Medium |
| Major Players | Imbria Pharmaceuticals, Angionetic Inc, Xylocor Therapeutics Inc, Caladrius Biosciences Inc |
please let us know !
Refractory Angina Treatment Market Analysis
The Global Refractory Angina Treatment Market is estimated to be valued at USD 200.1 Mn in 2024 and is expected to reach USD 312.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031. Refractory angina refers to a rare form of angina that does not respond to conventional treatments such as medication or surgery. This condition severely impacts the quality of life of those affected.
The market is expected to witness steady growth over the forecast period driven by the increasing prevalence of cardiovascular diseases along with limited treatment options for refractory angina. Various pipeline drugs and refractory angina treatment devices in clinical trials can potentially drive the market if approved. However, lack of awareness about refractory angina and high treatment costs remains major challenges to adoption.